Adamas Pharmaceuticals Inc


Adamas Pharmaceuticals Inc (ADMS) Analyst Explains Why Osmotica’s FDA Approved Drug Isn’t a Viable Threat

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw its shares crater by as much as 21% today on exceptionally high volume. This drop was triggered by …

Mizuho Forecasts 127% Upside for Adamas Pharmaceuticals Inc (ADMS) Following Higher-Than-Anticipated Gocovri Pricing

Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.

Adamas Pharmaceuticals Inc’ (ADMS) Gocovri Has Mizuho Confident Following Favorable Expert Call

Lead asset for ADMS indicates promising prospects in Parkinson’s along with valuable opportunity in MS.

Adamas Pharmaceuticals Inc Won FDA Approval; Shares Hit 52-Week High

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) investors are busy throwing a party this evening, following the news that the drug maker has won FDA approval …